Benihyp

Benihyp Uses, Dosage, Side Effects, Food Interaction and all others data.

Benihyp has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.

Benihyp reduces systolic and diastolic blood pressure as well as to present decreases in heart rate pulse after treatment. It is reported also a decrease urinary protein excretion and serum triglycerides. Different studies have shown benidipine anti-oxidative activity, stimulation of NO production, suppression of adhesion molecules expression, stimulation of osteoblast differentiation, suppression of the proliferation of vascular smooth muscle cells and mesangial cells, as well as myocardial protection. The enhancement of NO production is associated with the cardioprotective and antiartheriosclerotic effects of benidipine.

Trade Name Benihyp
Generic Benidipine
Benidipine Other Names Benidipine
Weight 4mg, 8mg
Type Tablet
Formula C28H31N3O6
Weight Average: 505.571
Monoisotopic: 505.22128573
Protein binding

Benidipine is highly bound to plasma proteins and the bound form can account for even 98% of the administered dose.

Groups Experimental
Therapeutic Class
Manufacturer J B Chemicals And Pharmaceuticals
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Benihyp
Benihyp

Uses

Benihyp is a synthetic dihydropyridine calcium channel blocker used to treat hypertension and angina pectoris.

Benihyp is a potent and long-lasting drug indicated for the treatment of cardiovascular diseases such as hypertension, renoparenchymal hypertension and angina pectoris.

Benihyp is also used to associated treatment for these conditions: Angina Pectoris, High Blood Pressure (Hypertension), Hypertension, Renal, Renal parenchymal hypertension

How Benihyp works

Benihyp is a tripe calcium channel inhibitor by inhibiting L, N and T type calcium channel. It presents a very long-lasting activity that can be explained by its high affinity for cell membranes from the DHP binding site; this characteristic indicated a long-lasting pharmacological activity of benidipine. The additional property of benidipine is the vascular selectivity towards peripheral blood vessels.

Toxicity

In preclinical studies, the LD50 of benidipine ranged from 87-384 mg/kg which is more than 100 times the needed dose to achieve anti-hypertensive action. There were no significant changes in histopathological heart examination. Benihyp showed no carcinogenic, antigenicity, teratogenic or mutagenic properties.

Volume of Distribution

Benihyp is highly distributed to the tissues mainly in the liver and kidneys and plasma. It does not present a high accumulation following repeated oral administrations.

Elimination Route

Benihyp is rapidly absorbed after oral administration reaching a maximum concentration within 2 hours. The short period of time needed for maximum concentration to get reached is a particular characteristic of benidipine when compared with other calcium channel blockers. The registered maximum concentration and AUC are dose-dependent and it can go from 0.55-3.89 ng/ml and 1.04-6.7 ng.h/ml respectively when administered in a dose of 2-8 mg.

Half Life

The elimination half-life of benidipine is registered to be of approximate 1 hour.

Elimination Route

The percentage of urinary excretion after oral administration is of approximate 36% of the administered dose. Most of the remaining dose is excreted in feces, making bile excretion the major elimination pathway of benidipine. From the eliminated drug, none of it is expressed in the form of the unchanged drug.

Innovators Monograph

You find simplified version here Benihyp

*** Taking medicines without doctor's advice can cause long-term problems.
Share